The Board's Role During a Clinical Hold
Few events reorganize a clinical-stage company as abruptly as a clinical hold. One communication from a regulator — sometimes over a safety signal, sometimes over a manufacturing or protocol issue, occasionally over something the company considers minor — and enrollment stops, dosing stops, the timeline the entire operating plan was built on dissolves, and a company that was executing is suddenly a company managing a crisis. The share price, if the company is public, may move violently before management has finished reading the letter.
This is exactly the kind of moment governance exists for, and it is exactly the kind of moment boards most often mishandle. The pressures are acute: management is overwhelmed and defensive, investors are frightened, the timeline is broken, and the temptation for directors is to do one of three unhelpful things — to react to the market rather than the facts, to try to solve the scientific problem themselves, or to retreat into passivity and let management sort it out. None of these is the board's job. This article is about what is.
First, Understand What a Hold Is and Is Not
A clinical hold is a regulatory order to pause some or all of a clinical investigation. It can be full or partial. It can arise from a safety signal seen in the trial, from a concern the agency has about the protocol or the informed consent, from a manufacturing or quality issue, from incomplete or deficient information in a submission, or from findings in related programs. The triggering causes vary enormously in what they imply about the underlying asset.
This variation is the first thing a board needs to internalize, because the instinct in the room — and certainly in the market — is to treat any hold as a verdict on the drug. It is not. A hold driven by a serious, drug-related safety signal is a fundamentally different event from a hold driven by a fixable manufacturing deviation or a documentation deficiency, even though both stop the program and both may hit the stock the same way on day one. The board's early work is largely about establishing which kind of event this actually is, and resisting the collapse of every hold into the most frightening interpretation.
It is equally important not to swing to the opposite error. Management, under stress and personally invested, will sometimes reach too quickly for the reassuring framing — "this is just a paperwork issue" — before the facts support it. The board's stance in the first days is neither panic nor premature reassurance. It is a disciplined insistence on understanding the actual cause before anyone, internally or externally, commits to a story about what it means.
The First Days: What the Board Actually Does
In the immediate aftermath, the board's contribution is not to generate answers — management and its regulatory advisors are far better positioned for that — but to ensure the right questions are being driven hard and the response is being run properly. A few things matter most.
Establish the facts before the narrative. The board should insist on understanding, as precisely as the available information allows, what the agency actually said, what specifically triggered the hold, and what the regulator has indicated it will require to lift it. This means the actual communication from the agency, not a summary of its gist. The gap between what a regulator wrote and how a stressed management team characterizes it is, in a crisis, wider than usual and more consequential than usual.
Confirm the response is being run by the right people. A hold response is a specialized undertaking — regulatory affairs, clinical, manufacturing or safety depending on the cause, often outside counsel and outside regulatory expertise. The board's early diligence is to confirm the company has mobilized the right capabilities and is not relying on an internal team that is out of its depth. Where the company lacks a capability the situation demands, surfacing that gap immediately is one of the most valuable things the board does in the first week.
Ensure disclosure is being handled correctly. For a public company, a hold is very often material and triggers disclosure obligations under real time pressure, frequently before management fully understands the situation. The board — typically through its relevant committee — has a genuine oversight role here: ensuring the company discloses what it must, when it must, accurately, without either downplaying a serious event or catastrophizing a manageable one. This is a domain where getting it wrong creates a second problem on top of the first, and where the board's oversight is not optional.
Protect management's focus. In the first days, the single most useful thing a board can do operationally is to not become an additional emergency management is forced to handle. A board that demands constant updates, calls individual directors' contacts, and floods the CEO with well-meaning but distracting input is subtracting from the response. The board should establish a clear, bounded communication rhythm — one point of contact, a defined update cadence — and then let the team work. Availability without interference is the posture.
The Questions That Matter Once the Dust Settles
After the initial scramble, the board moves into its more sustained and more important role: overseeing the path back and, harder, honestly assessing what the hold means for the asset and the company. This is where the real governance happens, and where boards that handled the first week well can still fail.
What does the agency actually require to lift the hold, and how confident are we we can deliver it? Some holds have a clear, bounded resolution path — supply this analysis, amend this protocol, fix this process. Others are open-ended, where the agency's requirement is essentially "convince us the drug is safe enough to continue," and the path to satisfying that is neither short nor certain. The board needs an honest read on which situation the company is in, and it should be alert to management's understandable inclination to present an open-ended problem as a bounded one.
What is this costing us — in time, in money, and in runway? A hold consumes cash while producing nothing, and it can extend timelines by quarters or longer. For a company with limited runway, a hold is not only a scientific and regulatory event but a financing event, and sometimes an existential one. The board should force an early, explicit accounting: how long can the company sustain a paused program, what is the realistic range of resolution timelines, and at what point does the hold threaten the company's ability to fund itself. This connects directly to whether an emergency raise, a bridge, or a harder strategic conversation needs to begin now rather than later.
Has our view of the asset actually changed? This is the hardest and most important question, and the one most likely to be avoided. A safety-driven hold in particular may be telling the company something real about the drug that no amount of regulatory response will change. The board has to hold open the possibility that the right answer is not "resolve the hold and continue" but "the hold has revealed something that changes the program's viability." Management, having built its identity around the asset, is the party least able to entertain this. It is precisely the board's role to keep the question alive without prematurely concluding the answer — to ensure that "how do we get the hold lifted" does not entirely crowd out "should we, given what we now know."
What is the contingency if the hold is not resolved, or not resolved in time? Good governance in a crisis means governing the downside branch explicitly. If the hold cannot be lifted on an acceptable timeline, what are the options — a different indication, a modified protocol, a partnership, a wind-down of that program to preserve resources for others? Boards that only ever discuss the resolution path are unprepared for the branch where resolution does not come, and unprepared boards make worse decisions under time pressure later.
The Traps
A few specific failure modes recur across boards navigating a hold, and naming them helps prevent them.
Reacting to the stock instead of the facts. For a public company, the market's reaction to a hold is immediate and often disproportionate, and it exerts enormous pressure on both management and the board to do something visible and fast. But the stock is reacting to incomplete information, frequently to the most frightening available interpretation. A board that lets share-price movement drive its decisions in the first days will make choices calibrated to the market's fear rather than the situation's reality. The discipline is to let the facts, not the ticker, set the pace of decision-making.
Trying to solve the science. Directors with scientific or medical backgrounds feel a strong pull, in a hold, to engage directly with the technical problem. Their expertise is genuinely valuable, but the board's role is oversight, not execution, and a director who slides into co-managing the technical response blurs a line that matters — and takes ownership of a problem the board is supposed to be governing, not solving. The contribution is to ensure the right people are on it and asking the right questions, not to become one of the people on it.
Premature reassurance, external or internal. Under pressure to calm investors or steady the team, there is a temptation to characterize the hold as more benign or more easily resolved than the facts yet support. This is dangerous in both directions: externally it can create disclosure and credibility problems if the situation proves worse; internally it can shut down the honest assessment of the asset that the board most needs to keep open. Confidence should track the facts, and no faster.
Letting the hold become permanent by neglect. Occasionally a hold on a secondary program is allowed to sit, unresolved and un-prioritized, because the acute pressure has passed and attention moved elsewhere. The board should ensure that every hold has an owner, a plan, and a decision point — including an explicit decision to formally abandon the program if that is the right answer, rather than letting it linger in an unresolved limbo that consumes attention and clouds the company's story.
The Underlying Principle
A clinical hold is a stress test of governance because it compresses every hard thing about overseeing a clinical-stage company into a short window: incomplete information, a frightened market, an overwhelmed and personally invested management team, real time pressure, and a decision that may be about the viability of the company's central asset. The board that navigates it well does a small number of things with discipline — insists on the actual facts before the narrative, confirms the response is properly resourced, protects management's focus, oversees disclosure, and, hardest of all, keeps alive the honest question of whether the hold has changed what the asset is worth.
None of that requires the board to solve the problem. It requires the board to ensure the problem is being solved by the right people, understood honestly, and evaluated for what it genuinely means rather than what everyone in the room most hopes it means. That is the whole of the board's job in a crisis, and it is enough.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.